ADVANZ PHARMA Corp. Limited
https://www.advanzpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ADVANZ PHARMA Corp. Limited
Kyorin Pharma To Shut Down US Subsidiary ActivX
Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.
Eisai To Shut Down H3 In Global R&D Restructuring
Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.
Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
Following Positive IIb Study Data, Can 180 Life Sciences Clear The Next Regulatory Hurdle?
180 Life Sciences has found that adalimumab can effectively treat nodule hardness and size in Dupuytren’s disease during a Phase IIb study. But, the company’s CEO Jim Woody tells Generics Bulletin, regulators in the UK and US have requested more information before they will press on with authorization.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- ADVANZ PHARMA
- ADVANZ PHARMA Corp. Limited
- Amdipharm Mercury Limited
- Concordia Healthcare Corp.
- Concordia International Corp.
- Concordia Laboratories, Inc.
- Concordia Pharmaceuticals, Inc.
- Covis Pharma S.à.r.l, Covis Injectables, S.à.r.l
- Correvio Pharma Corp